SynthesisFrontiers in oral health2026
The effectiveness of using recombinant human bone morphogenetic protein-2 in the reconstruction of alveolar clefts: a meta-analysis.
Synthesis in Frontiers in oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The purpose of this study was to examine the available evidence on the impact of using recombinant human bone morphogenetic protein-2 (rhBMP-2) in the reconstruction of alveolar clefts in terms of bone formation rate, bone volume, bone density, and postoperative complications. Methods: The PubMed, Embase, Web of Science, Scopus, and Cochrane databases were searched until April 2024. The outcomes included bone formation rate, bone volume, bone density, and postoperative complications. Studies comparing autologous iliac bone and rhBMP-2 for osteogenesis in patients with alveolar clefts were included. Results: Six studies were included. Treatment of an alveolar cleft with autologous iliac bone grafting resulted in higher bone formation, with statistically significant results after a 6-month follow-up period (MD -14.54; 95% CI -21.58 to -7.49; Conclusion: In this study, the application of rhBMP-2 showed no obvious advantage in the reconstruction of alveolar clefts in terms of bone volume and bone formation rate and may result in significant harm. However, further clinical research is required. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/reviewcoversheet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.